To print: Select File and then Print from your browser's menu

Title: New Slow-Release Lanreotide Effective for Active Acromegaly: Presented at ECE

"New Slow-Release Lanreotide Effective for Active Acromegaly: Presented at ECE"

By Alison Palkhivala LYON, FRANCE -- April 28, 2003 -– A new prolonged formulation of lanreotide, a somatostatin analog, decreases growth hormone and IGF-1 levels in patients with active acromegaly. In a study led by A. Colao from the department of molecular and clinical endocrinology, Frederico II University, Naples, Italy, 32 patients with active acromegaly received injections of a new prolonged, slow-release formulation of lanreotide (called lanreotide Autogel) 120 mg. The first three injections were each given 8 weeks apart. Afterward, additional injections (up to 7) were given 4, 6 or 8 weeks apart, depending on growth hormone levels. Overall, 15 patients were receiving therapy for the first time, and 17 had been unsuccessfully treated with trans sphenoidal surgery for a growth hormone secreting adenoma in the past. None of the patients had received treatment with a somatostatin analog before. The researchers presented their findings in a poster on April 27th, 2003, here at the 6th European Congress of Endocrinology. Treatment with the prolonged formulation of lanreotide produced average decreases in growth hormone from 18.8 to 10.5 ľg/L, p=0.03 and average decreases in insulin-like growth factor 1 (IGF-1) levels from 795.8 to 454.6 ľg/L, p<0.0001. These values represent a 45.5% drop in growth hormone levels and 36.9% drop in IGF-1 levels. Following treatment, 10 patients achieved a growth hormone level less than or equal to 2.5 ľg/L, and 7 experienced normalizations in their IGF-1 levels, for their age and gender. Both before and after treatment, patients who received trans sphenoidal surgery had lower growth hormone and IGF-1 levels than patients who had not undergone surgery. Treatment had a greater impact on the growth hormone and IGF-1 levels of the operated than the non-operated patients but was effective for both groups. Based on these findings, the authors concluded that the new slow-release formulation of lanreotide is effective at reducing growth hormone and IGF-1 levels in patients with active acromegaly, regardless of whether they had previously undergone surgery for this condition. [Study title: A New Slow-Release Formulation Of Lanreotide (Autogel) In Patients With Active Acromegaly: Preliminary Results Of A Multicenter, Open Clinical Study. Abstract: P0158.]

Copyright Š 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.